Introduction
Retinitis pigmentosa (RP) is a family of hereditary eye disorders characterized by progressive retinal degeneration (1, 2) . RP primarily affects rod photoreceptors, but secondary to rods, cone photoreceptors also degenerate. Due to the lack of rod functionality, patients suffer from night blindness at disease onset. Once cones are affected, the visual field becomes more and more constricted ("tunnel vision"), and finally, central vision is also impaired, leading eventually to complete blindness. Accordingly, clinical key symptoms of RP are night blindness, constricted visual fields, decreased visual acuity and color vision, and enhanced glare sensitivity. The typical fundus picture includes dark pigmentary clumps ("bone spicules") and attenuated retinal vessels as well as RPE atrophy. RP is genetically very heterogeneous and currently more than 50 RP genes are known. Many of the RP genes are preferentially or even exclusively expressed in rod photoreceptors (1) . Only a minor fraction of the RP genes are specific for other retinal cell types, e.g. retinal pigment epithelium (RPE) cells. Early success on gene replacement therapy for RPE-specific mutations resulted in a number of clinical trials with promising results (3) . However, since many of the disease-causing mutations concern (rod) photoreceptor-expressed genes, there is a need to develop treatments for photoreceptor-specific RP genes (1) .
Mutations in the genes encoding the two rod cyclic nucleotide-gated (CNG) channel subunits cause autosomal recessive RP (arRP) (4) . CNG channels are found in the plasma membrane of rod and cone photoreceptors and translate light-mediated concentration changes of the second messenger cGMP into voltage and calcium signals (4) . The rod CNG channel is a heterotetramer composed of three CNGA1 subunits and one CNGB1 subunit (5) . Mutations in CNGB1 (RP45 locus) are found in approximately 4% of autosomal recessive RP cases (1) . Knockout of CNGB1 in mice results in a phenotype that recapitulates the principal pathology of RP patients. In particular, CNGB1 knockout mice lack rod photoreceptor function (6, 7) . This functional defect is accompanied by a progressive degeneration of rods, and, secondary to this, a degeneration of the cones (6, 7) . The by guest on http://hmg.oxfordjournals.org/ Downloaded from degeneration progresses rather slow and results in loss of 10-20% of rods at 4 months, 30-50% at 6 months and 80-90% at one year of age. Finally, the loss of CNGB1a induces down regulation of several proteins of the phototransduction cascade and degradation of the CNGA1 subunit (6, 7) . In the present study we used CNGB1 knockout mice as a model for RP to evaluate AAV-mediated gene therapy as a potential treatment of RP caused by rod photoreceptor specific gene mutations. We show here that our gene replacement approach was able to restore rod CNG channel expression and localization, improve retinal function and vision guided behavior, and to delay retinal degeneration in CNGB1 -/-mice.
Results

Design and subretinal delivery of a gene therapy vector for rod-specific expression of CNGB1a
The relatively small packaging capacity (~5.2 kb) of AAV vectors (8-10) limits their use for the expression of large transgenes like CNGB1a. Because of the large size of the CNGB1a cDNA (3978 bp), there is only limited space left for cis-and trans-regulatory elements. To achieve high expression rates at the smallest possible vector genome size we decided to use only a single 221 bp long SV40 polyA sequence (see Materials and Methods) in combination with a 471 bp mouse rhodopsin promoter (-386 to + 86) (11). This vector allowed the incorporation of the full length CNGB1a cDNA without violating the 5.2 kb packaging limit of AAVs (8-10). We then packaged this construct (Fig. 1A ) into viral vector particles with Y733F-modified AAV8 capsid (12) and injected approx. 10 11 AAV genomic particles into the subretinal space of two-week-old CNGB1 -/-mice. The retinal site of treatment was monitored in vivo directly upon completion of the injection procedure and at subsequent time points using confocal scanning laser ophthalmoscopy (cSLO) (13) and optical coherence tomography (OCT) (14).
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Restoration of CNG channel expression in rod outer segments of CNGB1 -/-mice
We next analyzed the expression of CNGB1a in the retina of treated CNGB1 -/-mice. In a
Western blot analysis, we confirmed that subretinal delivery of our AAV vector led to expression of the full-length CNGB1a protein migrating at the expected size of approximately 250 kDa (Fig. 1B upper panel) . In addition, the 63 kDa CNGA1 subunit that is completely degraded in CNGB1 -/-mice was readily detectable in the injected retina (Fig. 1B, middle panel). Using immunohistochemistry we detected virally encoded CNGB1a protein in the treated, but not the untreated part of the retina. Figure 1C shows a representative overview image of a CNGB1 -/-retinal slice 40 days after treatment immunolabeled for CNGB1a. The treated area with high levels of CNGB1a expression corresponded to approximately one third of the retina. The CNGB1a protein localized almost exclusively to rod outer segments suggesting that transport mechanisms required for proper outer segment targeting of the channel are preserved in the treated knockout (Fig. 1C) . Figure 2 shows high resolution confocal scans from the treated (panels A, D and G) and untreated regions (panels B, E and H) of a CNGB1 -/-retina as well as from wild type control retina (panels C, F and I).
Importantly, viral treatment not only restored expression of CNGB1a (Figs. 2A) but also restored levels of the previously missing endogenous CNGA1 protein (Fig. 2D) , which now co-localized with CNGB1a in rod outer segments within the treated area (Figs. 2G). This suggests that AAV-mediated delivery of CNGB1a restored the expression of wild type-like heterotetrameric CNG channels in rod outer segments of treated mice. Moreover, the comparison with wild type mice showed that the treatment led to almost wild type levels of expression of CNGB1 and CNGA1 in treated CNGB1 -/-mice ( Fig. 2A , C-D and F). An improvement of photoreceptor outer segment morphology in the treated CNGB1 -/-retina could also be detected in vivo using optical coherence tomography (OCT) (Fig. 3A-B) . The typical outer retinal appearance in OCT with horizontal bands associated with the outer limiting membrane and the border between inner and outer segments (14, 15) (arrow in Fig.   3A ) was preserved in the treated eye, but not in the untreated one. We also performed confocal microscopy on histological retinal sections labeled with the photoreceptor outer 
CNGB1
-/-retina was comparable to the staining in the untreated. However, the length of the peripherin-2-positive outer segments was markedly increased in the treated (Fig. 3C) compared to the untreated (Fig. 3D ) part of the CNGB1 -/-retina.
Restoration of rod photoreceptor function in treated CNGB1 -/-mice
As expected, non-injected eyes (untreated eyes, UEs) of 8-week-old CNGB1 -/-mice did not
show the usual responses to dim light stimuli in dark-adapted (scotopic) Ganzfeld electroretinography (ERG), reflecting a lack of regular rod system activity ( For completeness, it should be mentioned that in a few cases, very small, irregular rod responses were present in CNGB1 -/-mice as previously described (5), which are attributed to homomeric CNGA1 channels that have escaped degradation. This fact is however mainly of theoretic interest as these contributions were too small to have any perceivable impact on the results shown.
To further probe whether the rod responses to repetitive stimuli were also restored, a scotopic flicker flash intensity series was done (Fig. 4C, D) . Contrary to untreated eyes, a recovery of the rod-driven flicker ERG responses was observed in AAV-treated eyes. In accordance with the approximate size of the treated area (about 1/3 rd of the total retina), rod- (Fig. 5A ). An example swim path for a wild type mouse on day 3 is shown in Taken together, these findings suggest that treated CNGB1 -/-mice gained the ability to navigate using information provided by the rod visual system.
We performed the test on days 4 and 5 under normal light conditions (see Materials and
Methods). Vision under these light conditions is mainly conferred by cone photoreceptors.
Since CNGB1 -/-mice have preserved cone function until 6 months of age (6), we expected all animal groups to be able to navigate under these test conditions. Wild type and treated CNGB1 -/-mice performed better than untreated CNGB1 -/-mice on day four, because they already learned the task under dim light conditions. However, untreated mice also started improving their performance until they reached similar levels of escape latencies like wild type and treated mice on day 5 ( Fig. 5A ).
During all tests the mice were allowed to swim for up to 120 s. If a mouse did not find the platform within 120 s, it was considered as an "error of omission". Wild type mice showed no (day 3) or almost no (day 2: 0.2 ± 0.2 %) errors of omission from the second test day on ( 
Gene therapy delays retinal degeneration in CNGB1 -/-mice
RP patients and CNGB1 -/-mice display a progressive retinal degeneration due to the loss of rod and cone photoreceptors, which needs to be ameliorated or halted in order to achieve long-term beneficial effects on vision. Having shown that our gene replacement therapy was able to restore rod photoreceptor function in ERG and to improve rod-mediated vision in the behavioral test, the question remained to what extent the treatment could also delay photoreceptor degeneration. Specifically, the progressive photoreceptor degeneration in CNGB1 -/-mice results in thinning of the outer nuclear layer to about half the size of wild type control mice at 6 months of age and to 1-2 rows of photoreceptors at one year (6) . The wild type retina contains 11-12 rows of photoreceptors. To test whether the treatment was able to delay the retinal degeneration we isolated the retina at 12 months post injection and analyzed the retinal histology. Figure 6A shows an overview image from a representative retinal slice of a treated knockout mouse at 12 months after treatment labeled with a CNGB1-specific antibody and the nuclear dye Hoechst 33342. The region with no CNGB1a expression revealed the expected thinning of the outer nuclear layer. However, in the treated part with high levels of CNGB1a expression 7-8 rows of photoreceptors remained indicating that the treatment significantly delayed photoreceptor cell loss (Fig. 6A ). In the untreated CNGB1 -/-retina Müller cells are activated and show high levels of GFAP immunoreactivity ( Fig 6B) (6) . In support of a beneficial effect on retinal degeneration, we observed a reduction of the GFAP signal to wild type levels at 12 months after treatment ( Fig. 6C-D ). An overview image from a treated CNGB1 -/-retina illustrating the treatment effect on Müller gliosis is shown in Fig. 6E . The beneficial effects on retinal degeneration go along with the normalization of cGMP metabolism in the CNGB1 -/-retina (Fig. 6G) . Within the untreated part of the retina, a profound accumulation of cGMP can be detected in photoreceptors (Fig. 6F ).
In accordance with the functional data, expression of CNGB1a also lowered cGMP in photoreceptors to levels comparable to wild type ( Fig. 6G-H) . As is typical for RP and its models, cone photoreceptors also start to degenerate in the CNGB1 -/-mouse secondary to rods although they are primarily unaffected. In untreated mice, cone degeneration becomes evident after 6 months of age (6) . To test for the beneficial effect of the treatment on cone photoreceptors, we stained the treated and untreated CNGB1 -/-retina with the cone marker cone arrestin (16) at 12 months post injection. We found that in the treated CNGB1-deficient retina, the morphology of cones was positively affected (Fig. 6I-K) . In this study we present data on the successful restoration of vision in the CNGB1 knockout mouse model of RP using AAV-mediated gene therapy. The treatment resulted in efficient expression of high levels of full length CNGB1a protein in rod photoreceptors that almost exclusively localized to outer segments. Importantly, this also resulted in restoration of the previously degraded endogenous CNGA1 protein, which is the second subunit of the native rod CNG channel (5). Following treatment, both proteins co-localized in rod outer segments and formed regular CNG channel complexes in the transduced area of the CNGB1 -/-retina.
We have previously shown that the vast majority of homomeric CNG channels (e.g. CNGA1
or CNGA3 only) cannot be transported into the photoreceptor outer segments and are rapidly degraded (6, 16, 27) . Only a minor fraction of CNGB1 -/-rods (3 out of 35 recorded cells, (6)) showed small (10 -15% of wild type) light responses. Accordingly, the levels of endogenous CNGA1 transcript and protein that are available for assembly with virally expressed CNGB1a seems to be the limiting factor that defines the amount of CNG channel complexes in the treated rod outer segments. Thus, the endogenous CNGA1 transcript levels act as an intrinsic safety barrier to ensure that the amounts of outer segment rod CNG channels cannot exceed wild type levels, which may prevent deleterious changes in photoreceptor Ca 2+ levels or membrane potential. In line with this, our treatment showed no adverse effects and revealed a prolonged preservation of photoreceptors up to the end of the follow-up period of 12 months.
In summary, the present study represents the first successful approach of restoration of vision in a retinal channelopathy model of RP. Importantly, we were able to demonstrate the restoration of visual system integrity and functionality by in vivo and in vitro analysis of retinal function and morphology, as well as vision guided behavior. Our data are very encouraging to launch AAV based gene therapy studies in human patients suffering from CNG channelopathies. 
Materials and Methods
Animals
Cloning and Production of rAAV Vectors
Cloning and mutagenesis were performed by standard techniques. All sequence manipulations were confirmed by sequencing. To construct pAAV2.1-Rho-CNGB1a-SV40, CNGB1a-SV40 plasmids followed by iodixanol-gradient (30) purification. The 40-60% iodixanol interface was further purified and concentrated by ion exchange chromatography on a 5 ml HiTrap Q Sepharose column using an ÄKTA Basic FPLC system (GE Healthcare, Munich, Germany) according to previously described procedures, followed by further concentration using Amicon Ultra-4 Centrifugal Filter Units (Millipore, Schwalbach, Germany). Physical titers (in genome copies/ml) were determined by quantitative PCR of CNGB1 (B1aqF: 5′-GAACTGGAACTGCTGGCTGAT-3′ and B1aqR: 5′-TGGAACACGGTGATGTCCAGGA-3′) using a LightCycler 480 (Roche Applied Science, Mannheim, Germany).
Subretinal rAAV Injections
As previously described (27), mice were anesthetized by subcutaneous injection of ketamine (66.7 mg/kg) and xylazine (11.7 mg/kg), and their pupils were dilated with tropicamide eye drops (Mydriaticum Stulln; Pharma Stulln GmbH, Germany). 1 µl rAAV particles were injected into the subretinal space using the NanoFil subretinal injection Kit (WPI, Germany) equipped with a 34 gauge beveled needle. The injection was performed free hand under a surgical microscope (Carl Zeiss, Germany). Special care was taken to avoid damage of the lens. The success of the procedure was monitored immediately following the injections using scanning laser ophthalmoscopy (13) and optical coherence tomography (14). If the procedure was not successful (severe damage like a full retinal detachment), the mice were excluded from further analysis. At the given age, this concerned about one eye out of five.
Electroretinograms
ERG analysis was performed at 6 weeks to 4 months after injection according to procedures described elsewhere (31, 32) . Single flash intensity and flicker frequency series data were available from 11 animals (one eye treated, one eye untreated). Scotopic flicker ERG series data were available from 11 animals (one eye treated, one eye untreated).
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Scanning-laser Ophthalmoscopy (SLO)
Retinal structures were visualized via a confocal scanning-laser ophthalmoscope (SLO, Heidelberg Retina Angiograph (HRA I)) according to previously described procedures (13).
The HRA features two argon wavelengths (488 nm and 514 nm) in the short wavelength range and two infrared diode lasers (795 nm and 830 nm) in the long wavelength range.
Laser wavelengths used for fundus visualization were: 514 nm (RF, red-free channel), and 488 nm for autofluorescent images (AF), with a barrier filter at 500 nm.
Spectral Domain Optical Coherence Tomography (SD-OCT)
SD-OCT imaging was done with a commercially available Spectralis™ HRA+OCT device Laser scanning confocal micrographs was performed using a LSM 510 meta microscope (Carl Zeiss, Germany) and images are presented as collapsed confocal z-stacks. Stainings were reproduced in  3 independent experiments.
Western Blot
For protein isolation from mouse retinas, the retinas were homogenized using a mortar and suspended in homogenization buffer (2% SDS, 50 mM Tris and proteinase inhibitor cocktail mix). After heating at 95°C for 15 minutes followed by centrifugation at 1000g for 10 minutes at 4°C, the resulting supernatant was used in Western blot analysis as previously described 
Visual water maze task
The Morris water maze test was originally described as a test for hippocampus-dependent learning (38) and used later with modifications as a test for vision-guided behavior (39). Mice were housed separately in an inverse12 hours light/dark cycle. The experiment was performed in the dark cycle. Mice were trained for three days (eight trials a day) to locate a stable platform (10 cm in diameter) at dim light conditions of 0,32 cd/m 2 to ensure that vision is totally conferred to the rod system. The platform was placed in a circular swimming pool (120 cm in diameter, 70 cm high, white plastic) filled with water. The starting position of the mouse was changed from trial to trial in a pseudorandom order whereas the platform was kept in a constant location. Distal cues in the testing room and the water maze, such as patterned cardboards, were provided as spatial references. Trials were terminated if the mouse climbed onto the platform or when it swam for two minutes. If the mouse did not find the platform, it was gently placed on the stable platform. After each trial the mouse was left on the platform for 10 seconds undisturbed before warmed using a heating lamp and transferred to the home cage. On day four and five, the experiment was performed under 
